+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 60Years +
All Genders
ID06377852

Study Comparing Two Dosing Approaches of CDK46 Inhibitors With Endocrine Therapy in Older Adults With Metastatic Breast Cancer to Improve Treatment Tolerance

Led by American Society of Clinical Oncology · Updated on 2026-11-02

500

Participants Needed

92

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating dosing strategies of CDK46 inhibitors in patients aged 60 and older with hormone receptor positive, HER2 negative metastatic breast cancer. The study compares the standard full-dose approach with a titrated dosing method that starts at a lower dose and increases as tolerated. The goal is to help more older patients tolerate side effects and stay on treatment longer to gain the most benefit from these drugs. Participants will choose either palbociclib or ribociclib combined with endocrine therapy, including aromatase inhibitors or fulvestrant. They will be randomly assigned to either the indicated dosing arm, starting at the full approved dose, or the titrated dosing arm, starting at a lower dose and escalating if well tolerated. The treatment cycles follow a 28-day schedule, with doses given orally on days 1-21. During the study, participants will be monitored for time to treatment discontinuation, toxicities, quality of life, dose adjustments, and healthcare utilization for up to 48 months. Patient-reported outcomes will be collected to understand tolerance better. Telehealth visits and remote consenting are allowed per institutional guidelines, supporting patient convenience throughout the trial.

CONDITIONS

Brief Title

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Research Team

J

Jackie Perez, MPH

C

Cindy MacInnis, MBA

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here